ERBC, Oncodesign, Cynbiose, Aepodia and PharmaLex sign a partnering agreement for preclinical and early clinical development
ERBC, Oncodesign, Cynbiose, Aepodia and PharmaLex a.r.c. and Belgium are pleased to announce the signature of a partnering agreement to provide the biotech and pharma industry with a full-service offering ranging from hit findings, preclinical research and regulatory developments to first-in-man trials. This established network of companies has seen an opportunity to provide greater added value services to clients worldwide.
As the biopharmaceutical industry moves towards the development of more complex drug candidates and highly personalized approaches, we are convinced that our collaborative and creative research organization network offers a successful solution to unlock the potential of innovation. The combination of expertise will speed up innovative projects from discovery to clinic. We bring together technological platforms, skills and knowledge, ability to set up an appropriate project governance structure within a comprehensive understanding of the drug development process.
The signing of this partnership agreement follows the 1st edition of the symposium held in September 2019 in Paris, France : «Innovative & Integrated Solution Providers in Translational Research to Develop Immunotherapies – Toward Next Generation of Solution Providers ».«Innovative & Integrated Solution Providers in Translational Research to Develop Immunotherapies – Toward Next Generation of Solution Providers ».
"Partnerships with experts have always played a key role in our daily mission to de-risk innovation and enhance R&D productivity of drug discovery. We are very pleased of this alliance with Oncodesign, Cynbiose, Aepodia and PharmaLex which today makes visible a landmark network of expertise in innovative drugs development," commented Serge Richard, PharmD, PhD, Chief Executive Officer of ERBC Group.